PCSK9 and atherosclerosis: PCSK9 inhibitor therapy is reserved as an adjunct to diet and maximally tolerated statin therapy for adults with HeFH or clinical ASCVD requiring additional lowering of LDLC, at a currently listed cost of $14,000–14,600/patient/year.